About NYXOID® nasal spray
NYXOID® nasal spray is a single-dose nasal spray used as part of the emergency treatment of an overdose of heroin or other opioid drugs1. Each pack contains 2 nasal sprays (2 single doses).
Based on the pharmacokinetic profile, it is anticipated that as a first line treatment of opioid overdose, NYXOID® nasal spray (1.8mg naloxone) will deliver therapeutic concentrations comparable with an IM 0.4mg naloxone standard of care2.
Two single doses of NYXOID® nasal spray, given three minutes apart, demonstrate a similar pharmacokinetic profile to 5 administrations of 0.4mg IM naloxone, given three minutes apart, both in terms of rate of rise of plasma concentrations and peak concentrations achieved2.
NYXOID®nasal spray is designed as an emergency rescue treatment only; the user must always seek medical help immediately by calling an ambulance (000) before using NYXOID®1.
NYXOID® nasal spray should be carried by anyone at risk of overdosing on an opioid, or witnessing an opioid overdose1. Close family or friends should know where to find NYXOID® in case of emergency.
What is Naloxone?
Naloxone has been used in routine practice for more than 40 years to reverse the effects of opioid overdose and in therapeutic situations.3
It reverses the effects of opioids (including respiratory depression) by competing directly with them at the opioid receptor.1
The risk of death can be reduced with the administration of naloxone as soon as an overdose is recognised. Naloxone is acknowledged as an important treatment option for opioid overdose and is included in the WHO Model List of Essential Medicines that countries should fund and supply.3
Reference: 1. NYXOID® nasal spray, Product Information, September 2018. 2. McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, Smith K, Strang J. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction 2018;113():484-493. 3. EMCDDA. Preventing opioid overdose deaths with take-home Naloxone. 2016. [Accessed March 2019.] Available at: http://www.emcdda.europa.eu/publications/insights/take-home-naloxone_en.
